AstraZeneca Pharmaceuticals LP struck out in its attempt to use a new pediatric orphan indication for Crestor (rosuvastatin) to block generic competition for seven more years. But the company was able to delay the launch of generic versions of the cholesterol-lowering blockbuster for 12 days, garnering it tens of millions of dollars in revenue.
On July 19, Judge Randolph Moss, of the U.S. District Court for the District of Columbia, denied AstraZeneca's motion for...





